Who should not get tetanus vaccine?

Infanrix   vaccine contraindications and precautions (Please see GlaxoSmithKline product insert for complete list):

• • Temperature of 105 F. or higher within 48 hours of a previous pertussis vaccination, not attributable to another identifiable cause;
  • Collapse or shock-like state (hypotonic-hyporesponsive episodes) within 48 hours of a previous pertussis vaccination;
  • Persistent crying lasting three hours or more within 48 hours of a previous pertussis vaccination;
  • Convulsions with or without fever, occurring within three days of a previous pertussis vaccination;
  • Serious allergic reaction to a previous pertussis vaccination;
  • Encephalopathy (coma, decreased level of consciousness, prolonged convulsions) within seven days of a previous pertussis vaccination not attributable to another identifiable cause;
  • Children with a progressive neurologic disorder, including infantile spasms, uncontrolled epilepsy, or progressive encephalopathy;
  • Apnea following intramuscular vaccination has been observed in some infants born prematurely. Infanrix vaccine product insert warns that the decision to vaccinate an infant born prematurely should take into consideration both the potential risks and possible benefits of vaccination;
  • If Guillain-Barré syndrome (GBS) occurred within six weeks of receiving a tetanus containing vaccine, assessment of the possible risks and potential benefits of receiving Infanrix should be carefully considered prior to vaccination;
  • The tip caps of prefilled Infanrix syringes contain latex and may cause an allergic reaction in persons sensitive to latex.

INFANRIX is FDA approved for use in infants and children between six weeks through six years of age. INFANRIX should not be administered to infants younger than six weeks or children older than six years of age.

Daptacel    vaccine contraindications and precautions (Please see Sanofi Pasteur product insert for complete list):

• • Temperature of 105 F. or higher within 48 hours of a previous pertussis vaccination, not attributable to another identifiable cause;
  • Collapse or shock-like state (hypotonic-hyporesponsive episodes) within 48 hours of a previous pertussis vaccination;
  • Persistent crying lasting three hours or more within 48 hours of a previous pertussis vaccination;
  • Convulsions with or without fever, occurring within three days of a previous pertussis vaccination;
  • Serious allergic reaction to a previous pertussis vaccination;
  • Encephalopathy (coma, decreased level of consciousness, prolonged convulsions) within seven days of a previous pertussis vaccination not attributable to another identifiable cause;
  • Children with a progressive neurologic disorder (such as infantile spasms, uncontrolled epilepsy, or progressive encephalopathy);
  • Apnea following intramuscular vaccination has been observed in some infants born prematurely. DAPTACEL vaccine product insert warns that the decision to vaccinate an infant born prematurely should take into consideration both the potential risks and possible benefits of vaccination.
  • If Guillain-Barré syndrome (GBS) occurred within six weeks of receiving a tetanus containing vaccine, assessment of the possible risks and potential benefits of receiving DAPTACEL should be carefully considered prior to vaccination. 

DAPTACEL is FDA approved for use in infants and children between six weeks through six years of age. DAPTACEL should not be administered to infants younger than six weeks or children older than six years of age.

Pediarix    vaccine contraindications and precautions (Please see GlaxoSmithKline product insert for complete list):

• • Temperature of 105 F. or higher within 48 hours of a previous pertussis vaccination, not attributable to another identifiable cause;
  • Collapse or shock-like state (hypotonic-hyporesponsive episodes) within 48 hours of a previous pertussis vaccination;
  • Persistent crying lasting three hours or more within 48 hours of a previous pertussis vaccination;
  • Convulsions with or without fever, occurring within three days of a previous pertussis vaccination;
  • Serious allergic reaction to a previous pertussis vaccination;
  • Encephalopathy (coma, decreased level of consciousness, prolonged convulsions) within seven days of a previous pertussis vaccination not attributable to another identifiable cause;
  • Children with a progressive neurologic disorder (such as infantile spasms, uncontrolled epilepsy, or progressive encephalopathy);
  • Sensitivity to any component of Pediarix, including yeast or neomycin and polymyxin B (antibiotics);
  • Apnea following intramuscular vaccination has been observed in some infants born prematurely. Pediarix vaccine product insert warns that the decision to vaccinate an infant born prematurely should take into consideration both the potential risks and possible benefits of vaccination.
  • The tip caps of prefilled Pediarix syringes contain latex and may cause an allergic reaction in persons sensitive to latex;
  • If Guillain-Barré syndrome (GBS) occurred within six weeks of receiving a tetanus containing vaccine, assessment of the possible risks and potential benefits of receiving Pediarix should be carefully considered prior to vaccination. 

Pediarix is FDA approved for use in infants and children between 6 weeks through 6 years of age. Pediarix should not be administered to infants younger than 6 weeks or children older than 6 years of age.

Kinrix   vaccine contraindications and precautions (Please see GlaxoSmithKline product insert for complete list):

• • Temperature of 105 F. or higher within 48 hours of a previous pertussis vaccination, not attributable to another identifiable cause;
  • Collapse or shock-like state (hypotonic-hyporesponsive episodes) within 48 hours of a previous pertussis vaccination;
  • Persistent crying lasting three hours or more within 48 hours of a previous pertussis vaccination;
  • Convulsions with or without fever, occurring within three days of a previous pertussis vaccination;
  • Serious allergic reaction to a previous pertussis vaccination;
  • Encephalopathy (coma, decreased level of consciousness, prolonged convulsions) within seven days of a previous pertussis vaccination not attributable to another identifiable cause;
  • Children with a progressive neurologic disorder (such as infantile spasms, uncontrolled epilepsy, or progressive encephalopathy);
  • Severe allergic reaction to any component of Kinrix, including neomycin and polymyxin B (antibiotics);
  • The tip caps of prefilled Kinrix syringes contain latex and may cause an allergic reaction in persons sensitive to latex;
  • If Guillain-Barré syndrome (GBS) occurred within six weeks of receiving a tetanus containing vaccine, assessment of the possible risks and potential benefits of receiving Kinrix should be carefully considered prior to vaccination. 

Kinrix is FDA approved for use in children between the ages of four and six years. Kinrix should not be administered to children younger than four years or older than six years of age.

Quadracel   vaccine contraindications and precautions (Please see Sanofi Pasteur product insert for complete list):

• • Serious allergic reaction following administration of a pertussis, tetanus, diphtheria, or polio containing vaccine or any ingredient of Quadracel vaccine;
  • Encephalopathy (coma, decreased level of consciousness, prolonged convulsions) within seven days of a previous pertussis vaccination not attributable to another identifiable cause;
  • Children with a progressive neurologic disorder (such as infantile spasms, uncontrolled epilepsy, or progressive encephalopathy);
  • Seizures within three days of a previous pertussis vaccination;
  • Temperature of 105 F. or higher within 48 hours of a previous pertussis vaccination, not attributable to another identifiable cause;
  • If Guillain-Barré syndrome (GBS) occurred within six weeks of receiving a tetanus containing vaccine, assessment of the possible risks and potential benefits of receiving Quadracel should be carefully considered prior to vaccination. 

Quadracel is FDA approved for use in children between the ages of four and six years. Quadracel should not be administered to children younger than four years or older than six years of age.

Pentacel   vaccine contraindications and precautions (Please see Sanofi Pasteur product insert for complete list):

• • Temperature of 105 F. or higher within 48 hours of a previous pertussis vaccination, not attributable to another identifiable cause;
  • Collapse or shock-like state (hypotonic-hyporesponsive episodes) within 48 hours of a previous pertussis vaccination;
  • Persistent crying lasting three hours or more within 48 hours of a previous pertussis vaccination;
  • Convulsions with or without fever, occurring within three days of a previous pertussis vaccination;
  • Serious allergic reaction to a previous pertussis vaccination;
  • Encephalopathy (coma, decreased level of consciousness, prolonged convulsions) within seven days of a previous pertussis vaccination not attributable to another identifiable cause;
  • Children with a progressive neurologic disorder (such as infantile spasms, uncontrolled epilepsy, or progressive encephalopathy)
  • Severe allergic reaction to any component of Pentacel, including neomycin and polymyxin B (antibiotics);
  • Apnea following intramuscular vaccination has been observed in some infants born prematurely. Pentacel vaccine product insert warns that the decision to vaccinate an infant born prematurely should take into consideration both the potential risks and possible benefits of vaccination;
  • If Guillain-Barré syndrome (GBS) occurred within six weeks of receiving a tetanus containing vaccine, assessment of the possible risks and potential benefits of receiving Pentacel should be carefully considered prior to vaccination. 

Pentacel is FDA approved for use in infants and children between six weeks through four years of age. Pentacel should not be administered to infants younger than six weeks or children older than four years of age.

VAXELIS   vaccine contraindications and precautions (Please see MCM Vaccine Company product insert for complete list):

• • Temperature of 105 F. or higher within 48 hours of a previous pertussis vaccination, not attributable to another identifiable cause;
  • Collapse or shock-like state (hypotonic-hyporesponsive episodes) within 48 hours of a previous pertussis vaccination;
  • Persistent crying lasting three hours or more within 48 hours of a previous pertussis vaccination;
  • Convulsions with or without fever, occurring within three days of a previous pertussis vaccination;
  • Serious allergic reaction to a previous dose of VAXELIS, any ingredient found in VAXELIS, or any other tetanus toxoid, diphtheria toxoid, pertussis-containing vaccine, hepatitis B vaccine, inactivated poliovirus vaccine, or H. influenzae type b vaccine;
  • Encephalopathy (coma, decreased level of consciousness, prolonged convulsions) within seven days of a previous pertussis vaccination not attributable to another identifiable cause;
  • Children with a progressive neurologic disorder (such as infantile spasms, uncontrolled epilepsy, or progressive encephalopathy);
  • Apnea following intramuscular vaccination has been observed in some infants born prematurely. VAXELIS vaccine product insert warns that the decision to vaccinate an infant born prematurely should take into consideration both the potential risks and possible benefits of vaccination;
  • If Guillain-Barré syndrome (GBS) occurred within six weeks of receiving a tetanus containing vaccine, assessment of the possible risks and potential benefits of receiving VAXELIS should be carefully considered prior to vaccination.

VAXELIS is FDA approved for use in infants and children between six weeks through four years of age. VAXELIS should not be administered to infants younger than six weeks or children older than four years of age.

Diphtheria and Tetanus Toxoids Adsorbed   vaccine contraindications and precautions (Discontinued by the manufacturer in 2023).  

• • Serious allergic or hypersensitivity reaction to a previous shot, or to any diphtheria or tetanus toxoid vaccine;
  • Apnea following intramuscular vaccination has been observed in some infants born prematurely. Diphtheria and Tetanus Toxoid Absorbed vaccine product insert warns that the decision to vaccinate an infant born prematurely should take into consideration both the potential risks and possible benefits of vaccination;
  • If Guillain-Barré Syndrome (GBS) occurred within six weeks of a previous tetanus toxoid vaccine, the risk of a recurrent case may be increased following vaccination with Diphtheria and Tetanus Toxoid Adsorbed.

Diphtheria and Tetanus Toxoid Adsorbed is FDA approved for use in infants and children between six weeks through six years of age. Diphtheria and Tetanus Toxoid Adsorbed should not be administered to infants younger than six weeks or children older than six years of age.

Adacel    vaccine contraindications and precautions (Please see Sanofi Pasteur product insert for complete list):

• • Moderate or severe acute illness (with or without fever) until the illness resolves;
  • Serious allergic or hypersensitivity reaction to a previous shot;
  • Encephalopathy (coma, decreased level of consciousness, prolonged convulsions) within seven days of a previous pertussis vaccination not attributable to another identifiable cause;
  • In adolescents, a progressive neurologic disorder, including progressive encephalopathy or uncontrolled epilepsy (convulsions);
  • In adults, an unstable neurologic condition, such as cerebrovascular events and acute encephalopathic conditions;
  • If Guillain-Barré Syndrome (GBS) occurred within six weeks of a previous tetanus toxoid vaccine, the decision to administer Adacel should carefully examine the possible risk and benefits of Adacel prior to vaccination;
  • Anyone who has experienced an Arthus-type hypersensitivity reaction following a previous dose of a tetanus toxoid vaccine should not receive Adacel more frequently than every 10 years;
  • The tip caps of prefilled Adacel syringes contain latex and may cause an allergic reaction in persons sensitive to latex.

Adacel is approved to be administered in persons between the ages of 10 and 64 years of age. A second dose of Adacel may be administered if there has been an interval of at least eight years between a prior Tdap vaccine dose. Adacel should not be administered to children younger than 10 years or adults older than 64 years.

Boostrix    vaccine contraindications and precautions (Please see GlaxoSmithKline product insert for complete list):

• • Serious allergic or hypersensitivity reaction to a previous shot;
  • Encephalopathy (coma, decreased level of consciousness, prolonged convulsions) within seven days of a previous pertussis vaccination not attributable to another identifiable cause;
  • In adolescents and adults, a progressive neurologic disorder, including progressive encephalopathy or uncontrolled epilepsy (convulsions);
  • If Guillain-Barré Syndrome (GBS) occurred within six weeks of a previous tetanus toxoid vaccine, the decision to administer Boostrix should carefully examine the possible risk and benefits of vaccination;
  • Anyone who has experienced an Arthus-type hypersensitivity reaction following a previous dose of a tetanus toxoid vaccine should not receive Boostrix more frequently than every 10 years;
  • The tip caps of prefilled Boostrix syringes contain latex and may cause an allergic reaction in persons sensitive to latex.

Boostrix is approved to be administered as a single dose in persons older than 10 years. Boostrix should not be administered to children younger than 10 years of age.

TDVAX   vaccine contraindications and precautions (Please see MassBiologics product insert for complete list) (Discontinued by the manufacturer in 2024.)  

• • Serious allergic or hypersensitivity reaction to a previous shot, or to any diphtheria or tetanus toxoid vaccine;
  • If Guillain-Barré Syndrome (GBS) occurred within six weeks of a previous tetanus toxoid vaccine, the decision to administer TDVAX should carefully examine the possible risk and benefits prior to vaccination;
  • Anyone who has experienced an Arthus-type hypersensitivity reaction following a previous dose of a tetanus toxoid vaccine should not receive TDVAX more frequently than every 10 years.

TDVAX is approved for use in adults and children seven years of age and older. TDVAX should not be administered to children younger than seven years.

TENIVAC   vaccine contraindications and precautions (Please see Sanofi Pasteur product insert for complete list):

• • Serious allergic or hypersensitivity reaction to a previous shot, or to any diphtheria or tetanus toxoid vaccine;
  • If Guillain-Barré Syndrome (GBS) occurred within six weeks of a previous tetanus toxoid vaccine, the decision to administer TENIVAC should carefully examine the possible risk and benefits prior to vaccination;
  • Anyone who has experienced an Arthus-type hypersensitivity reaction following a previous dose of a tetanus toxoid vaccine should not receive TENIVAC more frequently than every 10 years;
  • The tip caps of prefilled TENIVAC syringes contain latex and may cause an allergic reaction in persons sensitive to latex;
  • Administering TENIVAC vaccine more frequently than prescribed may result in the increased incidence and severity of adverse reactions.

TENIVAC is approved for use in adults and children seven years of age and older. TENIVAC should not be administered to children younger than seven years.